Skin conditions (dermatitis, eczema, psoriasis) Board decisions

The Board granted a 70 percent rating for PTSD with unspecified depressive disorder, panic disorder, and excoriation disorder with alcohol use disorder but denied other claims including erectile dysfunction, chronic sinusitis, allergic rhinitis, dermatitis, GERD, OSA, CFS, and IBS.

The Board denied an initial rating in excess of 50 percent for pseudofolliculitis barbae and an initial rating in excess of 70 percent for PTSD with GAD, finding that the evidence did not support a higher rating.

The Board denied increased ratings for several service-connected conditions, granted a 20 percent rating for left lower extremity radiculopathy, and remanded other issues.

The Board denied the veteran's claims for increased ratings and service connection, finding that the evidence did not support higher evaluations or service connection.

The Board granted service connection for a neck disability, back disability, GERD, hepatitis B, atopic dermatitis, and OSA. Tinnitus was denied.

The Board granted a 10 percent rating for pseudofolliculitis barbae (PFB) beginning February 10, 2024, based on the presence of painful papules.

The veteran was granted a total disability rating based on individual unemployability (TDIU) due to his service-connected disabilities preventing him from securing or following a substantially gainful occupation.

The Board denied the Veteran's claims for an increased rating and earlier effective date for migraines, as well as for an increased rating and earlier effective date for acne.

The Board denied service connection for various conditions, including IBS, gingivitis, myocarditis, abnormal heart (irregular heartbeat), muscle pain right hip flexors, muscle pain back, right knee disability, and exposure to hantavirus. The evidence did not show a current diagnosis of any of the claimed disabilities during the course of this appeal.

The Board granted service connection for an acquired psychiatric disorder and denied a compensable rating for bilateral hearing loss. The claims for GERD and psoriasis were remanded.

The Board denied the Veteran's claim for a higher initial rating for atopic eczematous dermatitis, finding that the evidence did not support a rating in excess of 10 percent.

The Board denied service connection for bilateral athletes' foot, onychomycosis and tinea nigra, a skin condition other than onychomycosis, bilateral hearing loss, bilateral plantar fasciitis, bilateral restless leg syndrome, breathing issues, left knee pain, lumbar spine disability, migraines, an acquired psychiatric disorder claimed as PTSD with anxiety and insomnia (also claimed as sleep disturbances), and tinnitus.

The appeal was dismissed as the proposed rating reductions for thoracolumbar spine strain and acne, and the initial ratings for bilateral hip disabilities were not properly appealed.

The Board denied service connection for right ear hearing loss and denied increased ratings for left ear hearing loss, degenerative disc disease, dermatitis, and epilepsy, grand mal.

The Board denied the Veteran's claim for service connection for dermatitis, claimed as skin symptoms, due to a lack of evidence showing a current disability and no in-service incurrence or aggravation.

The Board denied the claims for a rating in excess of 10 percent for pseudofolliculitis barbae and left ear hearing loss, as well as service connection for COPD. The claims for right knee arthritis and bilateral foot condition were remanded.

The Board remands the claims for service connection due to a failure by the VA contractor to provide an examination at a time when the Veteran could attend.

The Board denied a compensable rating for service-connected psoriasis and special monthly compensation prior to February 25, 2022.

The Board granted service connection for Lewy body dementia with parkinsonism and special monthly compensation (SMC) based on the need for aid and attendance, but denied service connection for skin disability, residuals of shrapnel wounds, bilateral upper and lower extremity peripheral neuropathy, and psychiatric disorder.

The Board granted the restoration of a 10 percent rating for pseudofolliculitis barbae, effective March 1, 2025, as the reduction was improper.